BlackRock Inc. lifted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 2.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,490,714 shares of the specialty pharmaceutical company’s stock after purchasing an additional 118,634 shares during the quarter. BlackRock Inc. owned about 7.43% of Jazz Pharmaceuticals worth $755,024,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently modified their holdings of the company. C WorldWide Group Holding A S boosted its position in shares of Jazz Pharmaceuticals by 0.7% in the 3rd quarter. C WorldWide Group Holding A S now owns 49,935 shares of the specialty pharmaceutical company’s stock worth $8,396,000 after purchasing an additional 343 shares in the last quarter. Adell Harriman & Carpenter Inc. boosted its position in shares of Jazz Pharmaceuticals by 3.0% in the 2nd quarter. Adell Harriman & Carpenter Inc. now owns 13,790 shares of the specialty pharmaceutical company’s stock worth $2,376,000 after purchasing an additional 400 shares in the last quarter. GAM Holding AG boosted its position in shares of Jazz Pharmaceuticals by 1.1% in the 2nd quarter. GAM Holding AG now owns 38,733 shares of the specialty pharmaceutical company’s stock worth $6,674,000 after purchasing an additional 433 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in shares of Jazz Pharmaceuticals by 28.2% in the 2nd quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,139 shares of the specialty pharmaceutical company’s stock worth $369,000 after purchasing an additional 470 shares in the last quarter. Finally, Andra AP fonden boosted its position in shares of Jazz Pharmaceuticals by 1.4% in the 3rd quarter. Andra AP fonden now owns 37,200 shares of the specialty pharmaceutical company’s stock worth $6,254,000 after purchasing an additional 500 shares in the last quarter. 92.30% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts recently issued reports on JAZZ shares. BidaskClub cut Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 12th. Stifel Nicolaus upped their price objective on Jazz Pharmaceuticals from $180.00 to $205.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Zacks Investment Research reaffirmed a “hold” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, November 13th. Leerink Swann upped their price objective on Jazz Pharmaceuticals from $200.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, August 17th. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $161.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, November 14th. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $189.76.
JAZZ stock opened at $151.20 on Monday. The company has a market capitalization of $9.12 billion, a P/E ratio of 15.82, a price-to-earnings-growth ratio of 0.91 and a beta of 1.06. Jazz Pharmaceuticals PLC has a 12-month low of $130.15 and a 12-month high of $184.00. The company has a current ratio of 4.29, a quick ratio of 4.16 and a debt-to-equity ratio of 0.52.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.32 by $0.26. The business had revenue of $469.37 million for the quarter, compared to analysts’ expectations of $482.64 million. Jazz Pharmaceuticals had a return on equity of 24.92% and a net margin of 28.09%. The firm’s quarterly revenue was up 14.0% on a year-over-year basis. During the same period in the prior year, the firm posted $3.22 EPS. As a group, analysts forecast that Jazz Pharmaceuticals PLC will post 11.6 EPS for the current year.
In other Jazz Pharmaceuticals news, Director Patrick G. Enright sold 10,130 shares of the business’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $168.76, for a total transaction of $1,709,538.80. Following the completion of the sale, the director now directly owns 19,884 shares in the company, valued at approximately $3,355,623.84. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction on Friday, September 14th. The shares were sold at an average price of $165.20, for a total transaction of $33,040.00. Following the sale, the executive vice president now owns 25,372 shares of the company’s stock, valued at $4,191,454.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,730 shares of company stock valued at $2,773,011. Company insiders own 3.90% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “BlackRock Inc. Has $755.02 Million Stake in Jazz Pharmaceuticals PLC (JAZZ)” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/12/03/blackrock-inc-has-755-02-million-stake-in-jazz-pharmaceuticals-plc-jazz.html.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.